← All trials
NCT06165991
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Dec 12, 2023
- Last posted
- Dec 29, 2023
- Enrollment
- 228
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong Province Qianfoshan HospitalLead sponsor
- Shandong Province Qianfoshan HospitalSponsor investigator
- Shandong first medical UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.